PURPOSE: Assess the intellectual and academic outcomes as well as risk factors associated with treatment for average-risk medulloblastoma in childhood using 23.4 Gy of craniospinal radiotherapy plus adjuvant chemotherapy. METHODS: From an overall sample of 379 enrolled in the parent study (COG A9961), 110 patients received a total of 192 assessments over more than 5 years with standardized IQ and academic achievement tests. Random coefficient models of the various outcomes were developed that incorporated covariates including chemotherapy regimen, age at diagnosis, sex, initial Full Scale IQ, and mutism. RESULTS: Participants in this study were found to be comparable to the overall sample in all demographic, disease, and treatment factors, except there were more gross total resections in the subsample undergoing intellectual and academic assessment. Major findings include significant decline in both intellectual and academic domains over time that were greater in children who were younger at diagnosis and had higher initial intelligence test scores. Children with mutism were at higher risk for initial effects on intelligence. No effects of sex were found. CONCLUSION: These results show progressive decline over several years post-treatment in standardized intellectual and academic scores. Despite recent improvements in therapies for these children, most notably a decrease dose of craniospinal radiation, they remain at risk. The pursuit of less toxic treatments, particularly for younger children, should continue. Neuropsychological surveillance should be routine at centers treating children with brain tumors.
RCT Entities:
PURPOSE: Assess the intellectual and academic outcomes as well as risk factors associated with treatment for average-risk medulloblastoma in childhood using 23.4 Gy of craniospinal radiotherapy plus adjuvant chemotherapy. METHODS: From an overall sample of 379 enrolled in the parent study (COG A9961), 110 patients received a total of 192 assessments over more than 5 years with standardized IQ and academic achievement tests. Random coefficient models of the various outcomes were developed that incorporated covariates including chemotherapy regimen, age at diagnosis, sex, initial Full Scale IQ, and mutism. RESULTS:Participants in this study were found to be comparable to the overall sample in all demographic, disease, and treatment factors, except there were more gross total resections in the subsample undergoing intellectual and academic assessment. Major findings include significant decline in both intellectual and academic domains over time that were greater in children who were younger at diagnosis and had higher initial intelligence test scores. Children with mutism were at higher risk for initial effects on intelligence. No effects of sex were found. CONCLUSION: These results show progressive decline over several years post-treatment in standardized intellectual and academic scores. Despite recent improvements in therapies for these children, most notably a decrease dose of craniospinal radiation, they remain at risk. The pursuit of less toxic treatments, particularly for younger children, should continue. Neuropsychological surveillance should be routine at centers treating children with brain tumors.
Authors: Taryn B Fay-McClymont; Danielle M Ploetz; Don Mabbott; Karin Walsh; Amy Smith; Susan N Chi; Elizabeth Wells; Jennifer Madden; Ashley Margol; Jonathan Finlay; Mark W Kieran; Douglas Strother; Girish Dhall; Roger J Packer; Nicholas K Foreman; E Bouffet; Lucie Lafay-Cousin Journal: J Neurooncol Date: 2017-04-12 Impact factor: 4.130
Authors: M Douglas Ris; Wendy M Leisenring; Pamela Goodman; Chongzhi Di; Jennie Noll; Wendy Levy; Leslie L Robison; Gregory T Armstrong Journal: Cancer Date: 2019-06-24 Impact factor: 6.860
Authors: Kevin R Krull; Kristina K Hardy; Lisa S Kahalley; Ilse Schuitema; Shelli R Kesler Journal: J Clin Oncol Date: 2018-06-06 Impact factor: 44.544
Authors: Lisa S Kahalley; M Douglas Ris; Anita Mahajan; M Fatih Okcu; Murali Chintagumpala; Arnold C Paulino; William E Whitehead; Charles G Minard; Heather H Stancel; Jessica Orobio; Judy J Xue; Emily A Warren; David R Grosshans Journal: Neuro Oncol Date: 2019-06-10 Impact factor: 12.300
Authors: Joseph Scafidi; Jonathan Ritter; Brooke M Talbot; Jorge Edwards; Li-Jin Chew; Vittorio Gallo Journal: Cancer Res Date: 2018-03-20 Impact factor: 12.701
Authors: Andrew M Heitzer; Alexandra M Villagran; Kimberly Raghubar; Austin L Brown; Miranda L Camet; M Douglas Ris; Jenny H Hanning; M Fatih Okcu; Arnold C Paulino; Murali Chintagumpala; Lisa S Kahalley Journal: J Neurooncol Date: 2019-11-28 Impact factor: 4.130
Authors: Jia Wei; Ling Ma; Chenglong Li; Christopher R Pierson; Jonathan L Finlay; Jiayuh Lin Journal: Curr Cancer Drug Targets Date: 2019 Impact factor: 3.428